``` REGISTERED CHARITY NUMBER: 292909 ``` ## **`Report of the Trustees and`** ``` Unaudited Financial Statements ``` ``` for the Year Ended 31 December 2020 ``` ``` for ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ``` Sandison Lang Limited 2 St Marys Road Tonbridge Kent TN9 2LB ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` Contents of the Financial Statements for the Year Ended 31 December 2020 ``` ||**`Page`**| |---|---| |**`Report of the Trustees`**|`1 to 11`| |**`Independent Examiner's Report`**|`12`| |**`Statement of Financial Activities`**|`13`| |**`Balance Sheet`**|`14`| |**`Notes to the Financial Statements`**|`15 to 22`| |**`Detailed Statement of Financial Activities`**|`23 to 24`| ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Report of the Trustees`** ## **`for the Year Ended 31 December 2020`** ``` Thetrusteespresenttheirreportwiththefinancialstatementsofthecharityfortheyear ended 31December2020.ThetrusteeshaveadoptedtheprovisionsofAccountingandReportingby Charities: StatementofRecommendedPracticeapplicabletocharitiespreparingtheiraccountsinaccordance with the FinancialReportingStandardapplicablein the UK and Republicof Ireland(FRS 102)(effective1 January 2019). ``` ## **`OBJECTIVES AND ACTIVITIES`** ## **`Objectives and aims`** ``` ObjectivesandaimsTheCancerTreatmentandResearchTrust(CTRT)whichwasfoundedin 1985, supportsworkmainlyin the departmentsof medicaloncologyat the WestLondonCancerCentrebased at CharingCrossHospitalandin thedepartmentofmedicaloncologyat theMountVernonCancerCentre, in Northwood,Middlesex.TheCTRTexiststosupporttreatmentandresearchintomanyformsof malignant diseaseandhasbeenparticularlyinvolvedinunderstandinghowcertaincancersdevelop,finding better waystomonitorthemanddevelopingnewanti-canceragents.Itremainscommittedtofunding research thatisnotadequatelyfundedeitherbythemajorcancercharities,theMRCorthe pharmaceutical industry. ``` ``` Page 1 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ## **`Report of the Trustees`** ``` for the Year Ended 31 December 2020 ``` ## **`ACHIEVEMENT AND PERFORMANCE`** ## **`Charitable activities`** ``` ThebenefitsoftheTrust'sworkaretheimprovementoftheunderstandingofandmonitoringof cancer, thedevelopmentofnewtreatmentsandthefundingofon-goingresearch,theeducationof future researchers,thedisseminationofresearchfindings(judgedbypublicationsandcitations),withthe goal being to assist people suffering from cancer. ``` ``` ThetrusteesarepleasedwiththeachievementsandperformanceoftheTrustin2020despite the difficulties caused by Covid-19 pandemic. ``` ``` TheCTRTin2020fundedpartofthelaboratoryrunningexpensesforseveralPhDand post-doctoral researchers at Charing Cross/Hammersmith Hospitals. ``` ``` In 2020atMountVernonCancerCentre,theCTRThasbeenfundingthesalaryofa clinicaltrialsofficer, a clinicaltrialsassistantaswellasaPhDresearchfellow,partofthesalariesofascientificofficer, PhD student and the expenses (bench and tuition fees) of a clinical research fellow doing a PhD. ``` ``` The research supported by the CTRT can be roughly split into the following areas: ``` - `Testicular and Ovarian Germ Cell Cancer (GCT)` - `Ovarian, uterine and rare gynaecological cancers` - `Lung Cancer` - `Gestational Trophoblastic Disease` - `Melanoma` - `Renal Cancer` - `Targeting tumour blood vessels` - `COVID-19 and Cancer` ``` Detailsaboutthe research,togetherwith the relevantpublicationsand studies,are availableon the Trust's website - cancertreatment.org.uk ``` ``` Page 2 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Report of the Trustees`** ``` for the Year Ended 31 December 2020 ``` ## **`FINANCIAL REVIEW Financial position Income level in 2020`** ``` TheCOVIDpandemicsignificantlyaffectedthelevelofunrestricteddonations,themainsourceof income for the Trust,with far feweropportunitiesfor interactionwith the relevantpublic.Closureof hospitals and fewerinteractionswiththepatientshasalsolimitedopportunitiesforfundraising.However,CTRThas a sufficientamountoffinancialreservesallowingtheTrusttocontinueresearchandcomplywiththe policy to hold funds amounting to at least 18 months' salary for those who is funded by the CTRT. ``` ``` In 2020CTRThas supporteda researchsalarybill of £90,621and another£65,580of runningexpenses and lab fees. ``` ## **`Reserves policy`** ``` Sufficientreservesare maintainedto ensurethat all expenses,as well as futureresearchcosts,are covered in the event no donations are received in any one year. ``` ``` For many years the CTRT receivedfunds to pay for researchstaff running clinicaltrials from pharmaceutical companiesand trialorganisations.IncreasinglythesefundshavebeenpaiddirectlytothelocalNHS Trusts whoemploythesestaff.As of 1stJanuary2008the accountsrelatedto MountVernonCancerCentre only include income and expenses actually paid into or out of CTRT accounts. ``` ``` Page 3 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ## **`Report of the Trustees`** ``` for the Year Ended 31 December 2020 ``` ## **`FUTURE PLANS Future studies`** ## `- New charity structure` ``` In 2020,theBoardofTrusteesforCTRTwereadvisedtoimplementa newstructureforthecharityin line withthe CharityCommission'srecommendations.The CTRThas lodgedan applicationforregistrationas a Charitable Incorporated Organisation (CIO) using one of the models recommended. ``` ## `- Investing in fundraising` ``` The CTRT updatedand approveda coupleof essentialpolicies.A smallgroup of CTRT volunteershave been identified.They are being veryhelpfulin the developmentof socialmediapresence.It is envisagedthat we willcontinuetoexpandthisgroupandexploreexpandingcurrentandimplementingnew fundraising initiatives in the next year. ``` ## `- Plans for research` ``` TheCTRTwillcontinuetosupportadiversevarietyofresearchintoseveraldifferenttypesof common cancerssuchaslung,ovarianandmelanomaandalsorarecancerssuchasgestational trophoblastic neoplasiaandovariangermcelltumours.Thisresearchincludesstudiesbothintheclinicandin the laboratoryfocusedondevelopingnovelbiomarkersandcancertreatmentsemployingthe latest technologies.Immunotherapycontinuestobeamajorareaofinterestinthecancerworldand CTRT continuestosupportleadingresearchstudyingtheeffectsofImmunotherapyintrophoblastic,lung and renal cancers. ``` ``` Details of previous research and further details about existing projects can be found on the website. ``` ## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`** ## **`Governing document`** ``` Thecharityiscontrolledbyitsgoverningdocument,adeedoftrustandconstitutesan unincorporated charity. ``` ``` The CancerTreatmentand ResearchTrust(CTRT)whichwas foundedin 1985,supportsworkmainlyin the departmentsofmedicaloncologyattheWestLondonCancerCentrebasedatCharingCross and HammersmithHospitals(ImperialCollegeHealthcareNHSTrust)andinthedepartmentof medical oncologyattheMountVernonCancerCentre,inNorthwood,Middlesex.Thecharityhasbeen controlled by its governing document, a deed of trust and constitutes an unincorporated charity. ``` ``` Page 4 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ## **`Report of the Trustees`** ``` for the Year Ended 31 December 2020 ``` ## **`STRUCTURE, GOVERNANCE AND MANAGEMENT Recruitment and appointment of new trustees`** ## `- Trustees` ``` AttheAGMonSept92019,MrRobinEllisonannouncedhisplanforretirementfromactiverolesin the CTRT.ProfessorGordonRustinalsoannouncedhisplantostepdownasChairofTrustees.Theyare both welcomedasHonorarytrustees.ItwasproposedattheAGMinJune2020,thattheroleofChairof the CTRT will be taken by Professor Marcia Hall, this will be ratified this year. ``` ``` We have welcomed Mr Russell Hallam, Partner IBB Law, Uxbridge as a new trustee. The other trusteesremain:Prof GordonRustin, Prof MichaelSeckl, Dr Paul Nathan,Dr Andreas Polychronis, DrAnandSharmaandDrDavidPinato.WeplantoactivelyseeknewTrusteesduring2021toachieve a broader range of expertise within the Board. ``` ## `- Administration` ``` The trusteesare particularlygratefulto LindaSwiftfor administratingthe Trustfor overthe last 15years. A newCTRTadministrator(part-time)wasappointedinNovember2020,MrsAnnaHoggett.Shewill work alongsideSharonWilmotfromNavigatorCorporateServices,whowilloverseethebook-keeping aspects forthecharity.AlreadygreatprogresshasmadetofinalisetheaccountsforDec2020,setupa new pensionschemeforouremployees(viaNEST)andtoexploretheamalgamationofseveralbank accounts onto a XERO platform to allow reconciliations into a single bank account. ``` ``` Atthequarterlytrustees'meetings,thetrusteesagreethebroadstrategyandareasofactivityfor the Trust,includingconsiderationofinvestment,reservesandriskmanagementandperformance.Theday to dayadministrationofgrantsandtheprocessingandhandlingofapplicationsisdelegatedtothe Trust Administrator. ``` ## **`Risk management`** ``` TheTrusteesareawareoftherisksaffectingtheTrustanditsworkandhaveensuredthatpoliciesare in place to mitigate the effect of these risks. ``` ## `- Financial risks and Investment` ``` TheTrustmaintainssubstantialreservestomeetitsoutstandinglong-termcommitments.The investment andmanagementofthosereservesareconsideredateachBoardmeeting;giventhenatureof the obligations,thedecisionhasbeentakentostayincash,despitetherisksofinflationandthe prevailing minimal interest rates. ``` ## `- Governance structure` ``` Thereviewofgovernancestructure,policiesandprocedureswascommencedandfollowingthat review, any recommendations made and agreed upon by the trustees will be implemented in the authorised order. ``` ``` Page 5 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ## **`Report of the Trustees`** ``` for the Year Ended 31 December 2020 ``` ## **`STRUCTURE, GOVERNANCE AND MANAGEMENT Conclusion`** ``` Research, either totally or partly funded by the CTRT led to over 38 publications in 2020. ``` ``` 1.MorganRD,BanerjeeS,HallM,ClampAR,ZhouC,HasanJ,OrbegosoC,TaylorS,TugwoodJ,Lyon AR, DiveC,RustinGJS,JaysonGC.PazopanibandFosbretabulininrecurrentovariancancer(PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecol Oncol. 2020 Mar;156(3):545-551. ``` ``` 2.ConstantineAlifrangis1,AnandSharma2,ShafiChowdhury3,SarahDuncan3,MarinaMilic2, Andrew Gogbashian4,SamitaAgarwal5,AnjuSahdev6,PeterWilson3,StephenHarland7,SaraStoneham 7, MichelleLockley8,GordonRustin2,TimothyOliver3,DanielBerney9,JonathanShamash. Single-agent carboplatinAUC10inmetastaticseminoma:Amulti-centreUKstudyof216patients.EurJCancer. 2020 Oct 8; S0959-8049(20)30486-X. doi: 10.1016/j.ejca.2020.08.031. Online ahead of print. Gynecol Oncol ``` ``` 3. M R Hall 1, H-M Dehbi2, S Banerjee3, R Lord4, A Clamp5, J A Ledermann6, S Nicum7, R Lilleywhite 8, R Bowen9,A Michael10,A Feeney11,R Glasspool12,A Hackshaw13,G Rustin.A phaseII randomised, placebo-controlledtrialoflowdose(metronomic)cyclophosphamideandnintedanib(BIBF1120) in advancedovarian,fallopiantubeorprimaryperitonealcancer.GynecolOncol.2020 Dec;159(3):692-698. doi: 10.1016/j.ygyno.2020.09.048. Epub 2020 Oct 16. ``` ``` 4. Neuropilin1 as a new potentialSARS CoV 2 infectionmediatorimplicatedin the neurologicfeatures and central nervous system involvement of COVID 19. ``` ``` 5.DaviesJ,RandevaHS,ChathaK,HallM,SpandidosDA,KarterisE,KyrouI.MolMedRep. 2020 Nov;22(5):4221-4226. doi: 10.3892/mmr.2020.11510. Epub 2020 Sep 15. PMID: 33000221 ``` ``` 6. SaraviS, KatsutaE, JeyaneethiJ, Amin H, KasparM, TakabeK, PadosG, DrenosF Hall M, KarterisE. H2A histonefamilymemberX (H2AX)upregulatedin ovariancanceranddemonstratesa utilityasa prognostic biomarker in terms of overall survival. J Clin Med. 2020 Sep 2;9(9): E2844. doi: 10.3390/jcm9092844 ``` ``` 7.OzaAM,Estevez-DizM,GrischkeE-M,HallM,MarméF,ProvencherD,UyarD,WeberpalsJI, Wenham RM,LaingNetal.ABiomarker-enriched,RandomizedPhaseIITrialofAdavosertib(AZD1775) Plus Paclitaxeland Carboplatinfor Womenwith Platinum-sensitiveTP53-mutantOvarianCancer.Clinical Cancer Research 26(18):4767-4776 15 Sep 2020 ``` ``` 8.CarterTJ,JeyaneethiJ,KumarJ,KarterisE,Glynne-JonesR,HallM.Identificationof Cancer-Associated CirculatingCellsinAnalCancerPatients.Cancers(Basel).2020Aug10;12(8):E2229. doi: 10.3390/cancers12082229. ``` ``` 9. RobertsC, StraussV, KopijaszS, GourleyC, Hall M, MontesA, AbrahamJ, ClampA, KennedyR, Banerjee S,FolkesLK,StratfordM,NicumS.ResultsofaphaseIIclinicaltrialof6-mercaptopurine(6MP) and methotrexateinpatientswithBRCA-defectivetumours.BrJCancer.2019Dec9. doi: 10.1038/s41416-019-0674-4. ``` ``` Page 6 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` for the Year Ended 31 December 2020 ``` ## **`Report of the Trustees`** ## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`** ``` 10.ClampAR,JamesEC,McNeishIA,DeanA, KimJW,O'DonnellDM,HookJ, CoyleC,BlagdenS, Brenton JD,NaikR,PerrenT,SundarS,CookAD,GopalakrishnanGS,GabraH,LordR,DarkG,EarlHM,Hall M, BanerjeeS,GlasspoolRM,JonesR,WilliamsS,SwartAM,StenningS,ParmarM,KaplanR,Ledermann JA Weeklydose-densechemotherapyinfirst-lineepithelialovarian,fallopiantube,orprimary peritoneal carcinomatreatment(ICON8):primaryprogressionfreesurvivalanalysisresultsfromaGCIGphase 3 randomisedcontrolledtrial.Lancet.2019Dec7;394(10214):2084-2095. doi: 10.1016/S0140-6736(19)32259-7. ``` ``` 11. BlagdenS, CookA, PooleC, HowellsL, McNeishI, DeanA, Kim J, O'DonnellD, HookJ, JamesE, White I, PerrenT,LordR,DarkG,EarlH,HallM,KaplanR,LedermannJ,ClampA.Weekly platinum-based chemotherapyversus3-weeklyplatinum-basedchemotherapyfornewlydiagnosedovarian cancer (ICON*):qualityofliferesultsofaphase3,randomised,controlledtrial.LancetOncol. 2020 Jul;21(7):969-77 doi: 10.1016/S1470-2045(20)30218-7 ``` ``` 12.BergaminiA,SarwarN,FerrandinaG,ScarfoneG,ShortD,AguiarX,CamnasioC,KaurB,Savage PM, CormioG,LimA,PignataS,MangiliG,SecklMJ.Canwereplaceadjuvantchemotherapywith surveillance forstageIA-Cimmatureovarianteratomasofanygrade?aninternationalmulticenteranalysis.Eur J Cancer. 2020 Sep; 137:136-143. PMID: 32763784 ``` ``` 13.Bouchard-FortierG,GhoraniE,ShortD,AguiarX,HarveyR,UnsworthN,KaurB,SarwarN,Seckl MJ. Followingchemotherapyforgestationaltrophoblasticneoplasia,doresiduallunglesionsincreasethe risk of relapse? Gynecol Oncol. 2020 Sep;158(3):698-701. PMID: 32654764 ``` ``` 14.DekeisterK,BolzePA,TodM,TodR,MassardierJ,LotzJP,HajriT,ColombanO,SecklMJ,Osborne R, FreyerG,GolfierF,YouB.Validationofanonlinetoolforearlypredictionofthefailure-riskin gestational trophoblasticneoplasiapatientstreatedwithmethotrexate.CancerChemotherPharmacol. 2020 Jul;86(1):15-24. doi: 10.1007/s00280-020-04086-0. Epub 2020 Jun 4. PMID: 32500221 ``` ``` 15.SavageP,WinterM,ParkerV, HardingV, Sita-LumsdenA, FisherRA,HarveyR, UnsworthN, Sarwar N, ShortD,AguiarX,TidyJ,HancockB,ColemanR,SecklMJ.Demographics,naturalhistoryand treatment outcomesofnon-molargestationalchoriocarcinoma:aUKpopulationstudy.BJOG. 2020 Aug;127(9):1102-1107. PMID: 32146729 ``` ``` 16.LokC,vanTrommelN,MassugerL,GolfierF,SecklM;ClinicalWorkingPartyoftheEOTTD. Practical clinicalguidelinesoftheEOTTDfortreatmentandreferralofgestationaltrophoblasticdisease.Eur J Cancer. 2020 May; 130:228-240. PMID: 32247260 ``` ``` 17.IbetoL,AntonopoulosA,GrassiP,PangPC,PanicoM,BobdiwalaS,Al-MemarM,DavisP,Davis M, NormanTaylorJ, AlmeidaP, JohnsonMR, HarveyR, BourneT, SecklM, ClarkG, HaslamSM, Dell A. Insights intothehyperglycosylationofhumanchorionicgonadotropinrevealedbyglycomicsanalysis.PLoS One. 2020 Feb 11;15(2):e0228507. PMID: 32045434 ``` ``` 18.FrijsteinMM,LokC,vanTrommelNE,TenKate-BooijMJ,MassugerL,vanWerkhovenE,Short D, AguiarX,FisherRA,KaurB,SarwarN,SebireNJ,SecklMJ.Lungmetastasesinlow-risk gestational trophoblastic neoplasia: a retrospective cohort study. BJOG. 2020 Feb;127(3):389-395. PMID: 31794098 ``` ``` Page 7 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` for the Year Ended 31 December 2020 ``` ## **`Report of the Trustees`** ## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`** ``` 19. CavorettoP, CioffiR, MangiliG, PetroneM, BergaminiA, RabaiottiE, ValsecchiL, CandianiM, Seckl MJ. APictorialUltrasoundEssayofGestationalTrophoblasticDisease..JUltrasoundMed. 2020 Mar;39(3):597-613. PMID: 31468566. ``` ``` 20.BalachandranK,SalawuA,GhoraniE,KaurB,SebireNJ,ShortD,HarveyR,HancockB,TidyJ,Singh K, SarwarN,WinterMC,SecklMJ.Whentostophumanchorionicgonadotrophin(hCG)surveillance after treatmentwithchemotherapyforgestationaltrophoblasticneoplasia(GTN):Anationalanalysison over 4,000patients.GynecolOncol.2019Oct;155(1):8-12.doi:10.1016/j.ygyno.2019.07.024.Epub 2019Jul 30. PMID: 31375268 ``` ``` 21.PinatoDJ,ZambelliA,Aguilar-CompanyJ,BowerM,SngC,SalazarR,BertuzziA,BrunetJ,Mesia R, SeguiE,BielloF,GeneraliD,GrisantiS,RizzoG,LibertiniM,MaconiA,HarbeckN,VincenziB,Bertulli R, OttavianiD, Carbo A, Bruna R, BenafifS, MarrariA, WuerstleinR, Carmona-GarciaMC, ChopraN, Tondini C, MirallasO,TovazziV,BettiM,ProvenzanoS,FotiaV,CruzCA,DallaPriaA,D'AvanzoF,Evans JS, Saoudi-GonzalezN,FelipE,GalaziM,Garcia-FructuosoI,LeeAJX,Newsom-DavisT,Patriarca A, Garcia-IllescasD,ReyesR,DileoP,SharkeyR,WongYNS,FerranteD,Marco-HernandezJ,Sureda A, MaluquerC,Ruiz-CampsI,GaidanoG,RimassaL,ChiudinelliL,IzuzquizaM,CabirtaA,FranchiM, Santoro A, Prat A, TaberneroJ, GennariA. Clinicalportraitof the SARS-CoV-2epidemicin Europeancancer patients. CancerDiscov.2020Jul31;10(10):1465-74.doi:10.1158/2159-8290.CD-20-0773.Epubaheadof print. PMID: 32737082; PMCID: PMC7668225. ``` ``` 22.PinatoDJ,LeeAJX,BielloF, SeguíE, Aguilar-CompanyJ, CarbóA, BrunaR, BowerM, RizzoG, Benafif S, CarmonaC,ChopraN,CruzCA,D'AvanzoF,EvansJS,GalaziM,Garcia-FructuosoI,DallaPria A, Newsom-DavisT,OttavianiD,PatriarcaA,ReyesR,SharkeyR,SngCCT,WongYNS,FerranteD,Scotti L, AvanziGC,BellanM,CastelloLM,Marco-HernándezJ,MollàM,PirisiM,Ruiz-CampsI,Sainaghi PP, GaidanoG,BrunetJ,TaberneroJ,PratA,GennariA.PresentingFeaturesandEarlyMortality from SARS-CoV-2InfectioninCancerPatientsduringtheInitialStageoftheCOVID-19Pandemicin Europe. Cancers(Basel).2020Jul8;12(7):1841.doi:10.3390/cancers12071841.PMID:32650523; PMCID: PMC7408670. ``` ``` 23.DettorreGM,DollyS,LoizidouA,ChesterJ,JacksonA,MukherjeeU,ZambelliA,Aguilar-Company J, BowerM,SngCCT,SalazarR,BertuzziA,BrunetJ,MesiaR,Sita-LumsdenA,SeguíE,BielloF,Generali D, GrisantiS,SeevaP,RizzoG,LibertiniM,MaconiA,MossC,RussellB,HarbeckN,VincenziB,Bertulli R, OttavianiD,LiñanR,MarrariA,Carmona-GarcíaMC,ChopraN,TondiniCA,MirallasO,TovazziV,Fotia V, CruzCA,Saoudi-GonzalezN,FelipE,RoquéA,LeeAJX,Newsom-DavisT,García-IllescasD,ReyesR, Wong YNS, FerranteD, ScottiL, Marco-HernándezJ, Ruiz-CampsI, PatriarcaA, RimassaL, ChiudinelliL, Franchi M, SantoroA, Prat A, GennariA, Van HemelrijckM, TaberneroJ, DiamantisN, PinatoDJ; OnCovidstudy group. Systemicpro-inflammatoryresponseidentifiespatientswithcancerwithadverseoutcomes from SARS-CoV-2infection:TheOnCovidInflammatoryScore.JImmunotherCancer.2021Mar;9(3): e002277. doi: 10.1136/jitc-2020-002277. PMID: 33753569; PMCID: PMC7985977. ``` ``` 24.NgK,VinnakotaK,SharmaA,KellyJ,DasguptaP,VasdevN.Urinarybiomarkerstomitigate diagnostic delayin bladdercancerduringthe COVID-19era.Nat Rev Urol.2020Dec 17:1-3.PMID:33335321 PMCID: PMC7745709 DOI: 10.1038/s41585-020-00419-z ``` ``` Page 8 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ## **`Report of the Trustees`** ## **`for the Year Ended 31 December 2020`** ## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`** ``` 25.AnandSharma,NikhilVasdev.UrinaryBiomarkersinBladderCancer:AReviewofthe Current Landscape and Future Directions. Urologic Oncology. Urol Oncol. 2021 Jan;39(1):41-51 ``` ``` 26.Joharatnam-HoganN,HochhauserD,ShiuKK,RushH,CrolleyV,WilsonW,SharmaA,Muhammad A, AnwarM,VasdevN,GoldsteinR,KantserG,SahaA,RajaF,BridgewaterJ,KhanK.Outcomesofthe 2019 novelcoronavirusin patientswithor withouta historyof cancer:a multi-centreNorthLondon experience. JoTher Adv Med Oncol. 2020 Sep 14. ``` ``` 27.SharmaA,SuleymanN,JonesO,VasdevNImmunotherapyinUrologicalTumors..Rev Urol. 2019;21(1):15-20. ``` ``` 28.EisenT, FrangouE, OzaB, RitchieAWS,SmithB, KaplanR, DavisID,StocklerMR,AlbigesL, Escudier B, LarkinJ, Bex A, JoniauS, HancockB, HermannGG, BellmuntJ, HodgkinsonE, StewartGD, BarberJ, Brown J, McMeneminR,NathanP,PickeringLM,ParmarMKB,MeadeA.AdjuvantSorafenibforRenal Cell CarcinomaatIntermediateorHighRiskofRelapse:ResultsfromtheSORCERandomizedPhase III Intergroup Trial. J Clin Oncol. 2020 Dec 1;38(34):4064-4075. doi: 10.1200/JCO.20.01800. Epub 2020 Oct 14. ``` ``` 29.DummerR,LebbéC,AtkinsonV,MandalàM,NathanPD,AranceA,RichtigE,YamazakiN,Robert C, SchadendorfD,TawbiHA,AsciertoPA,RibasA,FlahertyKT,PakhleN,CampbellCD,Gusenleitner D, MasoodA, BraseJC, GasalE, LongGV. CombinedPD-1,BRAF and MEK inhibitionin advanced BRAF-mutant melanoma:safetyrun-inandbiomarkercohortsofCOMBI-i.NatMed.2020Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5. ``` ``` 30.DummerR,AsciertoPA,NathanP,RobertC,SchadendorfDRationaleforImmune Checkpoint InhibitorsPlusTargetedTherapyinMetastaticMelanoma:AReview.JAMAOncol.2020Sep24. doi: 10.1001/jamaoncol.2020.4401. ``` ``` 31.LeeKA,ShawHM,BatailleV,NathanP,SpectorTD.Roleofthegutmicrobiomeforcancer patients receivingimmunotherapy:Dietaryandtreatmentimplications.EurJCancer.2020Oct;138:149-155. doi: 10.1016/j.ejca.2020.07.026. Epub 2020 Sep 2. ``` ``` 32.KeilholzU,AsciertoPA,DummerR,RobertC,LoriganP,vanAkkooiA,AranceA,BlankCU,Sileni VC, DoniaM,FariesMB,Gaudy-MarquesteC,GogasH,GrobJJ,GuckenbergerM,HaanenJ,HayesAJ, Hoeller C,LebbéC,LugowskaI,MandalàM,Márquez-RodasI,NathanP,NeynsB,BaggeRO,PuigS,Rutkowski P, SchillingB,SondakVK,TawbiH,TestoriA,MichielinO.ESMOconsensusconferencerecommendations on themanagementofmetastaticmelanoma:theESMOGuidelinesCommittee.AnnOncol.2020Jul 22: S0923-7534(20)39939-7 ``` ``` 33.MichielinO,vanAkkooiA,LoriganP,AsciertoPA,DummerR,RobertC,AranceA,BlankCU,Sileni VC, DoniaM,FariesMB,Gaudy-MarquesteC,GogasH,GrobJJ,GuckenbergerM,HaanenJ,HayesAJ, Hoeller C,LebbéC,LugowskaI,MandalàM,Márquez-RodasI,NathanP,NeynsB,BaggeRO,PuigS,Rutkowski P, SchillingB,SondakVK,TawbiH,TestoriA,ESMOconsensusconferencerecommendationson the managementof locoregionalmelanoma:theESMOGuidelinesCommittee.KeilholzU. Ann Oncol.2020 Jul 22:S0923-7534(20)39940-3 ``` ``` Page 9 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Report of the Trustees`** ``` for the Year Ended 31 December 2020 ``` ## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`** ``` 34. Lee KA, NathanP.CutaneousMelanoma- A Reviewof SystemicTherapies.ActaDermVenereol. 2020 Jun 3;100(11) ``` ``` 35.CebonJS,GoreM,ThompsonJF,DavisID,McArthurGA,WalpoleE,SmithersM,CerundoloV, Dunbar PR,MacGregorD,FisherC,MillwardM,NathanP,FindlayMPN,HerseyP,EvansTRJ,Ottensmeier CH, MarsdenJ, DalgleishAG,CorriePG,MariaM,BrimbleM,WilliamsG, WinklerS, JacksonHM, Endo-Munoz L,TutukaCSA,VenhausR,OldLJ,HaackD,MaraskovskyE,BehrenA,ChenW.Resultsofa randomized, double-blindphase II clinicaltrial of NY-ESO-1vaccinewith ISCOMATRIXadjuvantversusISCOMATRIX alone in participants with high-risk resected melanoma J Immunother Cancer. 2020 Apr;8(1) ``` ``` 36. WalkerJW, LebbéC, GrignaniG, NathanP, DirixL, Fenig E, AsciertoPA, SandhuS, MunhozR, Benincasa E, Flaskett S, Reed J, Engelsberg A, Hariharan S, Kasturi V. ``` ``` 37.EfficacyandsafetyofavelumabtreatmentinpatientswithmetastaticMerkelcell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020 Apr;8(1) ``` ``` 38. NathanP., The challengeof identifyingwhich stage III melanomapatientsneed adjuvanttreatment and with what. Ann Oncol. 2020 Jan;31(1):11-12. ``` ``` TheTrusteesareconfidentthattheCTRTwillcontinuetofundtheworkthatwillleadtoimprovements in the detection, monitoring and treatment of cancer and care for patients with cancer. ``` ## **`REFERENCE AND ADMINISTRATIVE DETAILS Registered Charity number`** ``` 292909 ``` ## **`Principal address`** ``` The Clocktower Mount Vernon Cancer Centre Rickmansworth Road Northwood Middlesex HA6 2RN ``` ## **`Trustees`** ``` Professor G Rustin R Ellison Dr. P Nathan Professor M Hall Chair of Trustees Professor M J Seckl Dr A Sharma Dr A Polychronis Dr D J Pinato R J Hallam ``` ``` Page 10 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Report of the Trustees`** ``` for the Year Ended 31 December 2020 ``` ## **`REFERENCE AND ADMINISTRATIVE DETAILS`** ## **`Independent Examiner`** ``` Mr Ryan Cottington FCCA Sandison Lang Limited 2 St Marys Road Tonbridge Kent TN9 2LB ``` ``` Approved by order of the board of trustees on 14 September 2021 and signed on its behalf by: ``` ``` Professor M Hall - Trustee ``` ``` Page 11 ``` ``` Independent Examiner's Report to the Trustees of Cancer Treatment And Research Trust ``` ## **`Independent examiner's report to the trustees of Cancer Treatment And Research Trust`** ``` I reportto the charitytrusteeson my examinationof the accountsof CancerTreatmentAnd Research Trust (the Trust) for the year ended 31 December 2020. ``` ## **`Responsibilities and basis of report`** ``` AsthecharitytrusteesoftheTrustyouareresponsibleforthepreparationoftheaccountsin accordance with the requirements of the Charities Act 2011 ('the Act'). ``` ``` I reportin respectofmyexaminationoftheTrust'saccountscarriedoutundersection145oftheAct and incarryingoutmyexaminationIhavefollowedallapplicableDirectionsgivenbytheCharity Commission under section 145(5)(b) of the Act. ``` ## **`Independent examiner's statement`** ``` Ihavecompletedmyexamination.Iconfirmthatnomaterialmattershavecometomyattention in connection with the examination giving me cause to believe that in any material respect: ``` `1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or` `2. the accounts do not accord with those records; or` `3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.` ``` Ihavenoconcernsandhavecomeacrossnoothermattersinconnectionwiththeexaminationto which attentionshouldbedrawninthisreportinordertoenableaproperunderstandingoftheaccountsto be reached. ``` ``` Mr Ryan Cottington FCCA Sandison Lang Limited 2 St Marys Road Tonbridge Kent TN9 2LB ``` ``` 14 September 2021 ``` ``` Page 12 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Statement of Financial Activities`** ## **`for the Year Ended 31 December 2020`** |`Unrestricted`
`fund`
`Notes`
`£`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
**`101,884`**
`Investment income`
`2`
**`102`**
**`Total`**
**`101,986`**
**`EXPENDITURE ON`**
`Raising funds`
**`19,833`**
**`Charitable activities`**
`Office expenses`
**`75,161`**
`Other`
**`-`**
**`Total`**
**`94,994`**
**`NET INCOME`**
**`6,992`**
**`RECONCILIATION OF FUNDS`**
**`Total funds brought forward`**
**`835,987`**
**`TOTAL FUNDS CARRIED FORWARD`**
**`842,979`**|`Restricted`
`fund`
`£`
**`126,111`**
**`-`**
**`126,111`**
**`-`**
**`115,837`**
**`-`**
**`115,837`**
**`10,274`**
**`146,123`**
**`156,397`**|**`2020`**
**`Total`**
**`funds`**
**`£`**
**`227,995`**
**`102`**
**`228,097`**
**`19,833`**
**`190,998`**
**`-`**
**`210,831`**
**`17,266`**
**`982,110`**
**`999,376`**|`2019`
`Total`
`funds`
`£`
`443,505`
`748`| |---|---|---|---| ||||`444,253`
`20,393`
`182,142`
`1,262`| ||||`203,797`| ||||`240,456`
`741,654`| ||||`982,110`| ``` The notes form part of these financial statements ``` ``` Page 13 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Balance Sheet`** ## **`31 December 2020`** |`Unrestricted`
`fund`
`Notes`
`£`
**`FIXED ASSETS`**
`Tangible assets`
`6`
**`457`**
`Investments`
`7`
**`6,469`**
**`6,926`**
**`CURRENT ASSETS`**
`Debtors`
`8`
**`-`**
`Cash at bank`
**`844,799`**
**`844,799`**
**`CREDITORS`**
`Amounts falling due within one year`
`9`
**`(8,746)`**
**`NET CURRENT ASSETS`**
**`836,053`**
**`TOTAL ASSETS LESS CURRENT LIABILITIES`**
**`842,979`**
**`NET ASSETS`**
**`842,979`**
**`FUNDS`**
`10`
`Unrestricted funds`
`Restricted funds`
**`TOTAL FUNDS`**|`Restricted`
`fund`
`£`
**`913`**
**`-`**
**`913`**
**`44,374`**
**`118,075`**
**`162,449`**
**`(6,965)`**
**`155,484`**
**`156,397`**
**`156,397`**|**`2020`**
**`Total`**
**`funds`**
**`£`**
**`1,370`**
**`6,469`**
**`7,839`**
**`44,374`**
**`962,874`**
**`1,007,248`**
**`(15,711)`**
**`991,537`**
**`999,376`**
**`999,376`**
**`842,979`**
**`156,397`**
**`999,376`**|`2019`
`Total`
`funds`
`£`
`1,501`
`6,469`
`7,970`
`-`
`978,806`
`978,806`
`(4,666)`
`974,140`
`982,110`
`982,110`
`835,987`
`146,123`
`982,110`| |---|---|---|---| ``` ThefinancialstatementswereapprovedbytheBoardofTrusteesandauthorisedforissue on 14 September 2021 and were signed on its behalf by: ``` ``` M Hall - Trustee ``` ``` The notes form part of these financial statements ``` ``` Page 14 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` Notes to the Financial Statements for the Year Ended 31 December 2020 ``` ## **`1. ACCOUNTING POLICIES`** ## **`Basis of preparing the financial statements`** ``` Thefinancialstatementsofthecharity,whichisapublicbenefitentityunderFRS102,have been preparedinaccordancewiththeCharitiesSORP(FRS102)'AccountingandReportingby Charities: StatementofRecommendedPracticeapplicabletocharitiespreparingtheiraccountsin accordance withtheFinancialReportingStandardapplicableintheUKandRepublicofIreland(FRS 102) (effective1January2019)',FinancialReportingStandard102'TheFinancialReporting Standard applicableintheUKandRepublicofIreland'andtheCharitiesAct2011.Thefinancial statements havebeenpreparedunderthehistoricalcostconvention,withtheexceptionofinvestments which are included at market value. ``` ## **`Financial reporting standard 102 - reduced disclosure exemptions`** ``` Thecharityhastakenadvantageofthefollowingdisclosureexemptionsin preparingthese financial statements,aspermittedbyFRS102'TheFinancialReportingStandardapplicableintheUK and Republic of Ireland': ``` - `the requirements of Section 7 Statement of Cash Flows.` ## **`Income`** ``` Allincomeis recognisedin theStatementofFinancialActivitiesoncethecharityhasentitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. ``` ## **`Expenditure`** ``` Liabilitiesarerecognisedasexpenditureassoonasthereisalegalorconstructive obligation committingthe charityto that expenditure,it is probablethat a transferof economicbenefitswill be requiredinsettlementandtheamountoftheobligationcanbemeasuredreliably.Expenditure is accountedforonanaccrualsbasisandhasbeenclassifiedunderheadingsthataggregateall cost relatedtothecategory.Wherecostscannotbedirectlyattributedtoparticularheadingsthey have been allocated to activities on a basis consistent with the use of resources. ``` ## **`Tangible fixed assets`** ``` Depreciationisprovidedatthefollowingannualratesinordertowriteoffeachassetover its estimated useful life. ``` ``` Computer equipment- 25% on reducing balance ``` ## **`Taxation`** ``` The charity is exempt from tax on its charitable activities. ``` ## **`Fund accounting`** ``` Unrestrictedfundscanbe usedin accordancewiththecharitableobjectivesat thediscretionof the trustees. ``` ``` Restrictedfunds can only be used for particularrestrictedpurposeswithin the objectsof the charity. Restrictionsarisewhenspecifiedbythedonororwhenfundsareraisedforparticular restricted purposes. ``` ``` continued... ``` ``` Page 15 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` Notes to the Financial Statements - continued for the Year Ended 31 December 2020 ``` ## **`1. ACCOUNTING POLICIES - continued`** ## **`Fund accounting`** ``` Furtherexplanationofthenatureandpurposeofeachfundis includedin thenotestothe financial statements. ``` ## **`2. INVESTMENT INCOME`** |`Deposit account interest`
`Dividends`|**`2020`**
**`£`**
**`102`**
**`-`**
**`102`**|`2019`
`£`
`25`
`723`| |---|---|---| |||`748`| ## **`3. TRUSTEES' REMUNERATION AND BENEFITS`** ``` Therewerenotrustees'remunerationorotherbenefitsfortheyearended31December2020 nor for the year ended 31 December 2019. ``` ## **`Trustees' expenses`** ``` Therewereexpensesof £139paid to 1 trusteefor the yearended31stDecember2020.(£255for 1 trustee for 31st December 2019). ``` ## **`4. STAFF COSTS`** ``` The average monthly number of employees during the year was as follows: ``` ||**`2020`**|`2019`| |---|---|---| |`Secretary/Administration`|**`1`**|`1`| ``` No employees received emoluments in excess of £60,000. ``` ``` continued... ``` ``` Page 16 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ## **`Notes to the Financial Statements - continued`** ## **`for the Year Ended 31 December 2020`** |**`5.`**
**`COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES`**
`Unrestricted`
`fund`
`£`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
`191,495`
`Investment income`
`748`
**`Total`**
`192,243`
**`EXPENDITURE ON`**
`Raising funds`
`20,393`
**`Charitable activities`**
`Office expenses`
`100,989`
`Other`
`25`
**`Total`**
`121,407`
**`NET INCOME`**
`70,836`
**`RECONCILIATION OF FUNDS`**
**`Total funds brought forward`**
`765,151`
**`TOTAL FUNDS CARRIED FORWARD`**
`835,987`|`Restricted`
`fund`
`£`
`252,010`
`-`
`252,010`
`-`
`81,153`
`1,237`
`82,390`
`169,620`
`(23,497)`
`146,123`|`Total`
`funds`
`£`
`443,505`
`748`| |---|---|---| |||`444,253`
`20,393`
`182,142`
`1,262`| |||`203,797`| |||`240,456`
`741,654`| |||`982,110`| ``` continued... ``` ``` Page 17 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Notes to the Financial Statements - continued for the Year Ended 31 December 2020`** ## **`6. TANGIBLE FIXED ASSETS`** |**`6.`**|**`TANGIBLE FIXED ASSETS`**|| |---|---|---| |||`Computer`| |||`equipment`| |||`£`| ||**`COST`**|| ||`At 1 January 2020`|**`3,538`**| ||`Additions`|**`350`**| ||`At 31 December 2020`|**`3,888`**| ||**`DEPRECIATION`**|| ||`At 1 January 2020`|**`2,037`**| ||`Charge for year`|**`481`**| ||`At 31 December 2020`|**`2,518`**| ||**`NET BOOK VALUE`**|| ||`At 31 December 2020`|**`1,370`**| ||`At 31 December 2019`|`1,501`| |**`7.`**|**`FIXED ASSET INVESTMENTS`**|| |||`Listed`| |||`investments`| |||`£`| ||**`MARKET VALUE`**|| ||`At 1 January 2020 and`|| ||`31 December 2020`|**`6,469`**| ||**`NET BOOK VALUE`**|| ||`At 31 December 2020`|**`6,469`**| ||`At 31 December 2019`|`6,469`| ||`There were no investment assets outside the UK.`|| ``` continued... ``` ``` Page 18 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ## **`Notes to the Financial Statements - continued for the Year Ended 31 December 2020`** |**`8.`**
**`DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
`Prepayments and accrued income`
**`9.`**
**`CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
`Other creditors`
**`10.`**
**`MOVEMENT IN FUNDS`**
`At 1/1/20`
`£`
**`Unrestricted funds`**
`General fund`
**`835,987`**
**`Restricted funds`**
`Restricted Fund`
**`146,123`**
**`TOTAL FUNDS`**
**`982,110`**
`Net movement in funds, included in the above are as follows:`
`Incoming`
`resources`
`£`
**`Unrestricted funds`**
`General fund`
**`101,986`**
**`Restricted funds`**
`Restricted Fund`
**`126,111`**
**`TOTAL FUNDS`**
**`228,097`**|**`2020`**
`2019`
**`£`**
`£`
**`44,374`**
`-`
**`2020`**
`2019`
**`£`**
`£`
**`15,711`**
`4,666`
`Net`
`movement`
`At`
`in funds`
`31/12/20`
`£`
`£`
**`6,992`**
**`842,979`**
**`10,274`**
**`156,397`**
**`17,266`**
**`999,376`**
`Resources`
`Movement`
`expended`
`in funds`
`£`
`£`
**`(94,994)`**
**`6,992`**
**`(115,837)`**
**`10,274`**
**`(210,831)`**
**`17,266`**| |---|---| ``` continued... ``` ``` Page 19 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` Notes to the Financial Statements - continued for the Year Ended 31 December 2020 ``` ## **`10. MOVEMENT IN FUNDS - continued`** ## **`Comparatives for movement in funds`** |**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**|`At 1/1/19`
`£`
`765,151`
`(23,497)`
`741,654`|`Net`
`movement`
`in funds`
`£`
`70,836`
`169,620`
`240,456`|`At`
`31/12/19`
`£`
`835,987`
`146,123`
`982,110`| |---|---|---|---| ``` Comparative net movement in funds, included in the above are as follows: ``` |**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
`192,243`
`252,010`
`444,253`|`Resources`
`Movement`
`expended`
`in funds`
`£`
`£`
`(121,407)`
`70,836`
`(82,390)`
`169,620`
`(203,797)`
`240,456`| |---|---|---| ``` continued... ``` ``` Page 20 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` Notes to the Financial Statements - continued for the Year Ended 31 December 2020 ``` ## **`10. MOVEMENT IN FUNDS - continued`** ``` A current year 12 months and prior year 12 months combined position is as follows: ``` |**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**|`At 1/1/19`
`£`
`765,151`
`(23,497)`
`741,654`|`Net`
`movement`
`in funds`
`£`
`77,828`
`179,894`
`257,722`|`At`
`31/12/20`
`£`
`842,979`
`156,397`
`999,376`| |---|---|---|---| ``` Acurrentyear12monthsandprioryear12monthscombinednetmovementinfunds,included in the above are as follows: ``` |**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
`294,229`
`378,121`
`672,350`|`Resources`
`Movement`
`expended`
`in funds`
`£`
`£`
`(216,401)`
`77,828`
`(198,227)`
`179,894`
`(414,628)`
`257,722`| |---|---|---| ``` continued... ``` ``` Page 21 ``` ``` CANCER TREATMENT AND RESEARCH TRUST ``` ``` Notes to the Financial Statements - continued for the Year Ended 31 December 2020 ``` ## **`11. RELATED PARTY DISCLOSURES`** ``` There were no related party transactions for the year ended 31 December 2020. ``` ``` Page 22 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Detailed Statement of Financial Activities`** ## **`for the Year Ended 31 December 2020`** |**`INCOME AND ENDOWMENTS`**
**`Donations and legacies`**
`Donations`
`Legacies`
**`Investment income`**
`Deposit account interest`
`Dividends`
**`Total incoming resources`**
**`EXPENDITURE`**
**`Raising donations and legacies`**
`Administrator`
`Events expenses`
**`Charitable activities`**
`Secretarial fees`
`Research salaries`
`Research expenses and lab fees`
`Research conferences/meetings`
`Postage and stationery`
`Computer expenses`
`Sundries`
`Depreciation of tangible fixed assets`
**`Support costs`**
**`Management`**
`Insurance`
`Carried forward`|`2020`
`£`
**`227,995`**
**`-`**
**`227,995`**
**`102`**
**`-`**
**`102`**
**`228,097`**
**`19,233`**
**`600`**
**`19,833`**
**`-`**
**`97,012`**
**`79,895`**
**`2,428`**
**`183`**
**`217`**
**`2,687`**
**`481`**
**`182,903`**
**`200`**
**`200`**|`2019`
`£`
`348,505`
`95,000`| |---|---|---| |||`443,505`
`25`
`723`| |||`748`| |||`444,253`
`17,280`
`3,113`| |||`20,393`
`1,200`
`37,451`
`119,884`
`12,235`
`4,767`
`631`
`416`
`694`| |||`177,278`
`-`
`-`| ``` This page does not form part of the statutory financial statements ``` ``` Page 23 ``` ## **`CANCER TREATMENT AND RESEARCH TRUST`** ## **`Detailed Statement of Financial Activities`** ## **`for the Year Ended 31 December 2020`** |**`Management`**
`Brought forward`
`Telephone`
**`Finance`**
`Bank charges`
**`Governance costs`**
`Accountancy`
`Professional fees`
`Total resources expended`
**`Net income`**|`2020`
`£`
**`200`**
**`477`**
**`677`**
**`70`**
**`4,805`**
**`2,543`**
**`7,348`**
**`210,831`**
**`17,266`**|`2019`
`£`
`-`
`608`| |---|---|---| |||`608`
`25`
`5,493`
`-`| |||`5,493`| |||`203,797`| |||`240,456`| ``` This page does not form part of the statutory financial statements ``` ``` Page 24 ```